Summary Lipid nanoparticles (LNPs) was a key driver in the success of the mRNA COVID vaccines. They protected and helped the mRNA to cross our cell membrane to produce the SARS-CoV-2 protein. However, the LNPs used today are far from optimal and improvement is needed to avoid side effects and make the more effective at smaller dose. The project will use microfluidic to mix more biocompatible and homogenous LNPs with improved properties. This will also pave the way for much wider applications of mRNA medicine targeted to other organs and tissues.